Aims/hypothesis Elevated plasma levels of NEFA impair insulin action. Given the positive linear correlation between NEFA released by adipocytes and plasma NEFA levels, identification of mechanisms controlling adipocyte lipolysis and NEFA release could provide a guide to new therapies for insulin resistance and type 2 diabetes. Methods Short hairpin RNA-mediated gene ablation was used to determine the functions of c-Jun N-terminal kinase (JNK)1 and JNK2 in adipocytes. Results Combined JNK1/JNK2 deficiency drastically increased basal glycerol release, whereas individual JNK1-or JNK2-deficiency had no effect, indicating that JNK1/JNK2-deficiency enhances basal lipolysis, whereas the alternate subtype compensates for a single JNK subtype deficiency in the regulation of basal lipolysis. The profoundly increased glycerol release associated with JNK1/JNK2-deficiency was not accompanied by a concomitant increase in NEFA release over time. In addition, JNK1-deficiency, but not JNK2-deficiency, drastically decreased NEFA release as compared with that in JNKintact cells, a result of increased NEFA re-esterification. In microarray, quantitative RT-PCR and western blotting, JNK1-, JNK2-and JNK1/JNK2-deficiencies selectively upregulated many genes involved in NEFA management, without affecting the expression of genes involved in insulin signalling. Assays using reporter genes driven by peroxisome proliferator-activated receptor γ (PPAR-γ)-responsive promoters indicate distinct roles for JNK1 and JNK2 in regulating the transcriptional effects of PPAR-γ. Conclusions/interpretation While JNK1 and JNK2 have shared roles in the regulation of basal lipolysis, JNK1 has a more profound role in supporting baseline NEFA release. Inhibition of JNK1 activity in adipocytes has potential therapeutic uses for management of elevated circulating NEFA levels at the onset of insulin resistance.
are less clear. Adipose tissue is the largest NEFA depot. The amount of NEFA released from adipocytes, determined mainly by the balance between lipolysis and intra-adipocyte NEFA re-esterification, is linearly related to plasma NEFA levels [7, 8] . Moreover, insulin-mediated inhibition of NEFA release from adipocytes reduces plasma NEFA levels [9] [10] [11] [12] . Thus, identification of the regulatory mechanisms controlling adipocyte lipolysis and NEFA release should provide a guide to new therapies for insulin resistance, a root cause of obesitylinked type 2 diabetes.
The c-Jun N-terminal kinases (JNKs), key regulators of both cell proliferation and growth, and apoptosis and metabolism [13] [14] [15] [16] [17] , are activated by NEFA [18, 19] and pro-inflammatory cytokines [15] . Distinct genes encode three JNK subtypes. JNK3 is produced mainly in brain, heart and testis, whereas JNK1 and JNK2 are produced ubiquitously [14] . JNK activates several transcription factors including c-JUN [14] , activating transcription factor 2 (ATF-2) [20] and ELK1, member of ETS oncogene family (ELK1) [21] , and modulates the activities of IRS-1 [17, 22] , IRS-2 [19] and peroxisome proliferator-activated receptor γ (PPAR-γ) [23] . The JNK pathway is highly relevant in this context, because JNK activity is elevated in insulin target tissues during obesity [24] and mice lacking JNK1, but not JNK2, are resistant to obesity induced by high-fat diet and have improved insulin sensitivity [24] . However, a genetic dissection of the involvement of JNK2 in overall insulin sensitivity may be masked by in vivo factors including JNK1 redundancy and the cross-talk between JNK subtypes. Indeed, the role of JNK2 in the regulation of body weight and insulin sensitivity is unmasked only in mice with heterozygous disruption of Jnk1 (also known as Mapk8), but not in mice with full JNK1 activity [25] . Additionally, macrophage-specific ablation of Jnk2 (also known as Mapk9), but not Jnk1, reduces atherosclerosis [26] , while germ-line deletion of Jnk2 reduces destructive insulitis and protects against type 1 diabetes in mice [27] , indicating differential physiological functions for JNK subtypes, depending on cell context. In light of these findings, it is important to identify the intrinsic roles of JNK1 and JNK2 in the regulation of adipocyte function, in the context of lipolysis and NEFA release, which is essential to systemic insulin sensitivity [6, 28] .
Here, short hairpin RNA (shRNA)-mediated gene silencing of Jnk1 and/or Jnk2 in a model fat cell line, 3T3-L1 adipocytes, was used to directly and definitively test lipolysis and NEFA release in the absence of JNK1 and/or JNK2. Both shared and distinct roles for JNK1 and JNK2 in the regulation of adipocyte gene expression and function are reported and analysed in the context of obesitylinked diabetes.
Methods
Plasmids Short hairpin RNA constructs targeting Jnk1 (5′-AGCCAGTCAGGCAAGAGAT-3′) and Jnk2 (5′-GCCTTGC GCCACCCGTATA-3′) mRNAs were subcloned into pRetroSuper retroviral vector (Netherlands Cancer Institute, Amsterdam, the Netherlands). After transfection into the packaging cells, the supernatant fraction containing the retroviruses was collected and used to infect 3T3-L1 pre-adipocytes. The luciferase reporter genes driven by the Pck1 and PPAR-γ-response elements (PPRE) promoters, and the cDNA encoding PPARG2 have been described previously [29] .
Cell culture 3T3-L1 cells were purchased from American Type Culture Collection (Rockville, MD, USA), maintained as fibroblasts and differentiated into adipocytes using standard protocol except that troglitazone (1 μmol/l) was added during the first 3 days of differentiation to achieve more uniform adipocyte differentiation (> 99%). The adipocytes were used within 10 days of induction of differentiation. After ∼30 passages, the differentiation rates decline to ∼80 to 85%. For this reason, new batches of cells were revived from frozen stocks to maintain greater than 95% of adipocyte differentiation in all four cell types.
Semi-qRT-PCR Total RNAs were isolated from indicated sources. Each sample of first-strand cDNA was synthesised from 1 μg of total RNA. PCR reactions were performed for 31 cycles, which falls within the previously identified linear range for PCR amplification of Jnk mRNAs. Primers for amplification of Jnk1 were 5′-TTCCCAGCTGACTCAGA GCATAAC-3′ (forward), and 5′-TAGTCATCTACAGCAG CCCAGAGG-3′ (reverse); for Jnk2 were: 5′-GGTCCTCC CTCCTGAGCCTAGAT-3′ (forward), and 5′-GTGTTCTG AGGCCGCTCTCCTAC-3′ (reverse).
Western blot analysis Equal amounts of protein were resolved by SDS-PAGE, electroblotted onto a nitrocellulose membrane, and immunoblotted with indicated antibodies. Bound antibodies were detected using the ECL reagents (GE Healthcare, Piscataway, NJ, USA). For a list of suppliers of antibodies used, see Electronic supplementary material (ESM).
Microarray analysis Total RNA was isolated from JNKintact and JNK1-, JNK2-and JNK1/JNK2-deficient 3T3-L1 adipocytes. Replicate samples of each cell type were analysed using Affymetrix mouse MG430A 2.0 arrays. A detailed description of microarray data collection and analysis is provided in the ESM.
Lipolysis assay After 16 h of serum starvation, various adipocytes were incubated with DMEM containing 300 to 450 μmol/l BSA and 25 mmol/l HEPES. After 10, 30, 60 and 90 min of incubation, 50 μl of medium was removed and replenished with 50 μl of fresh medium. After 120 min, the medium was completely removed. NEFA and free glycerol concentrations were determined using colorimetric kits (Wako Chemicals, Richmond, VA, USA). Protein concentrations were used to normalise sample values. Lipid loading and the NEFA re-esterification assay are described in the ESM.
Statistical analysis Comparisons were performed using ANOVA (two-or three-way). Duncan's multiple-range test was used post hoc to compare differences between and within the various treatments and groups. A value of p< 0.05 was used as the level of statistical significance. All values are expressed as mean ± SEM.
Results

JNK1
-and/or JNK2-deficiency do not impair 3T3-L1 preadipocyte differentiation We used a retroviral vector to deliver shRNAs against endogenous Jnk1 and/or Jnk2 mRNA into proliferating 3T3-L1 pre-adipocytes and achieved stable and highly efficient (∼100%) transduction of shRNAs into target cells. The recombinant retrovirus integrates a single copy of the viral genome into the host genome, ensuring stable expression of shRNAs in all offspring passages of the infected cells. Thus, retroviralmediated gene delivery permits analysis of large pools of stably infected cells with minimal intrinsic clone-to-clone variation. Control cells were 3T3-L1 pre-adipocytes infected with the empty vector, ruling out the possibility of retroviral infection-and/or antibiotic selection-mediated toxicity as a source of the observed phenotypic variation.
According to semi-quantitative RT (qRT)-PCR, retroviral delivery of Jnk1 shRNA drastically reduced Jnk1 mRNA levels from levels seen in adipocytes expressing vector only or Jnk2 shRNA (Fig. 1a) . The Jnk1 shRNA did not affect endogenous JNK2 (Fig. 1a) . Similarly, retroviral delivery of Jnk2 shRNA reduced Jnk2 mRNA without affecting the Jnk1 mRNA level (Fig. 1a) . Finally, coexpression of Jnk1 and Jnk2 shRNAs greatly reduced Jnk1 and Jnk2 mRNA levels (Fig. 1a) .
Microarray analysis revealed no detectable Jnk1 mRNA in adipocytes expressing Jnk1 shRNA or both Jnk1 and Jnk2 shRNAs (Table 1) . Similarly, Jnk2 mRNA levels were undetectable in adipocytes expressing Jnk2 shRNA or both Jnk1 and Jnk2 shRNAs. Jnk1 or Jnk2 mRNA was unaltered in adipocytes expressing the shRNA against the alternate JNK subtype ( Table 1 ). The effects of JNK subtype-specific shRNA on JNK1 and JNK2 protein mass paralleled the mRNA data (Fig. 1b) . Jnk1 shRNA selectively reduced JNK1 protein production but not that of JNK2. Jnk2 shRNA greatly reduced JNK2 levels, whereas there was little change in JNK1 levels. Tubulin levels were unaffected (Fig. 1b) . Thus, the effects of Jnk1 and Jnk2 shRNAs are subtype-specific with respect to mRNA expression and protein production.
Control (JNK-intact), JNK1-, JNK2-and JNK1/JNK2-deficient 3T3-L1 pre-adipocytes were generated and their differentiation was monitored. Three days after induction, all four cell lines had accumulated fat droplets, and after 10 days ∼100% of the cells were adipocytes (Fig. 1c) . Thus, deficiency of JNK1, JNK2 or both together does not impair cellular lipid accumulation during adipocyte differentiation. This concurs with previous data indicating that neither JNK1 or JNK2 is indispensable for adipose development in mice [24, 25] .
Combined JNK1/JNK2-deficiency accelerates baseline triacylglycerol hydrolysis without affecting NEFA release, whereas silencing JNK1, but not JNK2, decreases NEFA release We compared baseline lipolysis in JNK-intact, JNK1-, JNK2-and JNK1/JNK2-deficient adipocytes. In control JNK-intact adipocytes, basal triacylglycerol hydrolysis increased media glycerol concentration over a 120 min period (Fig. 2a) . Glycerol release from JNK1/JNK2-, JNK1-and JNK2-deficient cells was higher than that from JNK-intact cells at 10 min (p=0.0003). However, at later times differences were not significant except for the JNK1/ JNK2-deficient adipocytes, in which glycerol release increased by 44 to 154% over 120 min (p<0.0003 at all timepoints) (Fig. 2a) . Thus, in the regulation of basal glycerol production, JNK1/JNK2 deficiency enhances basal glycerol release, whereas the alternate subtype compensates for a single JNK subtype deficiency. These effects are the same in the presence and absence of insulin ( Fig. 2b) : only JNK1/ JNK2-deficiency affected glycerol release as seen by a 57 to 146% increase in media glycerol concentration (10 min, p<0.01; 30 min, p<0.004; 60 -120 min, p<0.0001).
According to ANOVA, insulin did not affect timedependent increases in media glycerol concentrations in JNK-intact and JNK1/JNK2-deficient cells (Fig. 2a,b) . In contrast, insulin increased glycerol release in JNK1-deficient (64%, p=0.01) and JNK2-deficient (34%, p= 0.004) cells at 120 min. These data indicate that JNK1/ JNK2-deficiency is more important than insulin in the regulation of glycerol release.
The media NEFA concentrations increased 46% (p< 0.006) in JNK-intact cells only at 120 min, whereas media NEFA concentrations for JNK1-, JNK2-and JNK1/JNK2-deficient cells did not change with time (Fig. 2c) . Insulin decreased net NEFA release in JNK-intact cells only at prolonged incubations (−30% at 120 min, p<0.03), but did not further suppress NEFA release in JNK1-and/or JNK2-deficient cells (Fig 2c,d ). JNK-intact adipocytes exhibited parallel increases in NEFA and glycerol release (Fig. 2a,c) . In contrast, the profoundly increased glycerol release from JNK1/JNK2-deficient adipocytes was not accompanied by a concomitant increase in NEFA release over time (Fig. 2c ). This suggests that NEFA re-esterification is much higher in JNK1/JNK2-deficiency. Intriguingly, JNK1-deficiency, but not JNK2-deficiency, decreased NEFA release from the levels seen in JNK-intact cells in the absence (p<0.02 for all time-points except for 10 min) (Fig. 2c ) and the presence of insulin (p<0.01 for all time-points except for 10 min) (Fig. 2d) . Collectively, these data suggest that JNK1 and JNK2 have overlapping roles in the regulation of baseline lipolysis, whereas JNK1 has a predominant role in promoting basal NEFA release in adipocytes.
JNK1-and JNK1/JNK2-deficiencies increase the rate of NEFA re-esterification The discrepancy between glycerol and NEFA release in JNK1/JNK2-deficient cells and the diminished NEFA release from JNK1-deficient cells could be due to increased intracellular NEFA re-esterification. To test this hypothesis, we compared the kinetics of NEFA release in the four cell types in the presence of triacsin C, which blocks NEFA incorporation into triacylglycerol by inhibiting acyl-CoA synthetase [30, 31] . Triacsin C accelerated the rates of NEFA release; the differences in media NEFA concentrations were significant (p<0.0001) as early as 30 min and lasted for at least 120 min in all four cell types. Intriguingly, triacsin C abolished the differences in NEFA release between JNK-intact and JNK1-deficient cells (Fig. 2e) , indicating that enhanced NEFA re-esterification reduces the baseline NEFA release that is associated with JNK1-deficiency. Notably, JNK1/JNK2-deficient cells had the highest NEFA release at some time-points (60 and 90 min, compared with JNK-intact cells; p<0.03) (Fig. 2e) , indicating increased intrinsic lipolytic activity in JNK1/ JNK2-deficient cells at these time-points. These data suggest that JNK1-deficiency is both necessary and sufficient to enhance NEFA re-esterification in adipocytes. While accelerated NEFA re-esterification reduces NEFA release in JNK1-deficient cells, this effect was masked by the increased lipolysis in JNK1/JNK2-deficient cells.
JNK1 and/or JNK2-deficiency selectively upregulates adipocyte genes involved in triacylglycerol turnover Genomewide expression profiling, qRT-PCR and western blotting were used to determine whether differences in NEFA release associated with subtype-specific JNK-deficiency could be linked to specific genes, particularly those coding for proteins involved in triacylglycerol metabolism and storage. Despite a normal cellular lipid accumulation and adipocyte phenotype, DNA microarray clearly revealed that JNK1-and JNK2-deficiency altered adipocyte gene transcription ( Table 1) . The baseline expression levels of 623 genes were different in control and JNK1-deficient adipocytes. Of these, 425 showed at least a twofold decrease, whereas 198 genes showed an at least twofold increase in steadystate mRNA levels. Similarly, the basal expression levels of 571 and 658 genes were affected by JNK2-and JNK1/ JNK2-deficiency, respectively. Of these, 431 (JNK2-defi- cient) and 361 (JNK1/JNK2-deficient) genes were repressed, whereas 140 (JNK2-deficient) and 297 (JNK1/ JNK2-deficient) genes were upregulated by at least twofold (Fig. 3) . Interestingly, JNK1-, JNK2 and JNK1/JNK2 deficiency altered many of the same target genes in the same way (Table 1) . Repressed Gene Ontology clusters in JNK1-and/or JNK2-deficiency include immune and inflammatory responses, cytoskeleton, cell adhesion molecules and both secreted and extracellular matrix proteins. By contrast, upregulated Gene Ontology clusters include those involved in lipid, carbohydrate and protein metabolism. We also identified genes that responded specifically to either JNK1-or JNK2-deficiencies (Fig. 3) . Significantly upregulated common target genes include the lipogenic genes Pparg, Cebpa, Slc2a4, Scd2, Acsl1, Lpin1, Pck1, Pcx, Gk and Fasn, and the lipolytic genes Ces3, Pnpla2, Abhd5 and Lipe (Table 1) . However, genes whose encoded proteins are involved in insulin signalling such as Insr, Irs1 and Gsk3b were not affected by JNK1-and/or JNK2-deficiency, neither were the mRNA levels of common adipocyte markers Adipoq and Cfd or signalling proteins Ikbkb and Mapk14 (Table 1) . Thus, upregulation was selective for genes involved in triacylglycerol synthesis, hydrolysis and NEFA re-esterification, and closely related to adipocyte function.
Real-time qRT-PCR was performed to confirm upregulation of eight adipocyte-abundant genes (Pparg, Cebpa, Dgat1, Pcx, Pepck, Pnpla2, Abhd5 and Lipe) in various JNK-deficient cells (Fig. 4) . Of eight genes, seven showed similar expression patterns as revealed by both qRT-PCR and DNA microarray (Fig. 4a-g ). Although microarrays show increased Pparg mRNA levels in JNK1-(105%), JNK2-(106%) and JNK1/JNK2-deficient cells (67%) ( Table 1) , qRT-PCR revealed similar Pparg mRNA levels among the four cell types (Fig. 4h) . Moreover, according to western blot analysis, PPAR-γ protein levels were similar in the four cell types (data not shown). The discrepant observations could derive from intrinsic differences in the underlying principles of qPCR and microarray. Nevertheless, any differences in Pparg mRNA levels among the four cells types did not result in changes in PPAR-γ protein mass. The coordinated upregulation of multiple PPAR-γ target genes including Pepck, Cebpa and Gk (Table 1) supports the notion that increased PPAR-γ activity is probably involved in the upregulation of PPAR-γ target genes in JNK-deficient cells.
By western blotting, further induction of PEPCK protein was confirmed in cells with combined JNK1/JNK2-deficiency (359%, by densitometry) and JNK2-deficiency (152%); JNK1-deficient cells, however, showed decreased PEPCK protein mass compared with JNK-intact cells (−79%) (Fig. 5) . The molecular mechanism(s) underlying the reduction in PEPCK protein mass mediated by JNK1-deficiency remains unclear. However, the decreased PEPCK protein level did not lead to increased NEFA release in JNK1-deficient cells (Fig. 2b) , indicating a possible functional compensation from other genes involved in NEFA re-esterification such as glycerol kinase (Table 1 ) and/or increased intracellular NEFA utilisation including NEFA incorporation into phospholipids and oxidation.
JNK1-, JNK2-and JNK1/JNK2-deficiency differentially affect PPAR-γ-dependent gene transcription Based on our microarray studies suggesting the concomitant suppression of clusters of genes involved in immune and inflammatory response and cell adhesion, as well as upregulation of genes for adipocyte energy management in JNK1-and/or JNK2- . Fold changes were calculated using the average changes in gene expression in JNK1-, JNK2-and JNK1/JNK2-deficient adipocytes, relative to JNK-intact adipocytes. Genes with an average of a twofold or greater change in expression levels were included. For the entire set of microarray data, see ESM Table 1 deficient adipocytes (Table 1) , we hypothesised that the link from JNK1-and/or JNK2-deficiency to adipocyte gene expression might be altered production or function of a transcription factor with overlapping transactivation and transrepression activities. One attractive candidate is PPAR-γ, a master regulator of adipocyte differentiation and function [32] [33] [34] and a negative regulator of inflammatory cytokine production in macrophages [35] [36] [37] .
Given that PPAR-γ is a member of the ligand-dependent nuclear receptor superfamily and a phosphorylation target of JNK [38] , we tested the impact of various forms of JNKdeficiency on two PPAR-γ-responsive promoters: Pepck promoter (−2250/+69), which is upregulated by PPAR-γ and has well-characterised PPAR-γ responsive elements (PPRE); and a synthetic promoter containing multimerised PPRE. In JNK-intact 3T3-L1 pre-adipocytes, exogenous PPAR-γ activated Pepck promoter (81%, p < 0.0001) (Fig. 6a) in the presence of troglitazone. Despite baseline activity similar to that of the JNK-intact cells, in a JNK1-deficient cell background exogenous PPAR-γ increased Pepck promoter expression 283% (p<0.0001) in the presence of troglitazone, representing a 120% increase (p< 0.0001) relative to JNK-intact cells and the highest stimulation among the four cell types (p < 0.0001) (Fig. 6a) . By contrast, JNK2-deficiency reduced basal (−21.5%, p=0.01), but had no effect on troglitazonestimulated Pepck promoter expression as compared with JNK-intact cells (Fig. 6a) . Intriguingly, in the presence of troglitazone, combined JNK1/JNK2-deficiency stimulated PPAR-γ-dependent Pepck promoter expression by only 106% (p <0.0001), a 44% reduction relative to that seen in JNK1-deficient cells (p<0.0001). This suggests that endogenous JNK1 activity represses and JNK2 activity promotes the ligand-dependent transactivation function of PPAR-γ. The inhibitory activity of JNK1 is dominant, whereas the stimulatory action of JNK2 is revealed only when JNK1 is absent.
When the PPRE-driven luciferase reporter gene was used, JNK1-deficient cells exhibited 64% higher basal (p< 0.0001) and 70% enhancement of troglitazone-stimulated (p < 0.0001) luciferase activity over JNK-intact cells (Fig. 6b) , again demonstrating that JNK1 represses the transcription activation function of PPAR-γ. Consistent with our findings with the Pepck promoter, the enhancement of liganded PPAR-γ activity associated with JNK1-deficiency was attenuated by the simultaneous loss of JNK2 (−27%, p<0.0001). JNK2-deficiency alone did not affect baseline or PPAR-γ-dependent PPRE promoter expression as compared with JNK-intact cells (Fig. 6b) . Taken together, these data suggest that while JNK1 suppresses and JNK2 stimulates PPAR-γ activity, overall endogenous JNK activity inhibits both ligand-independent and liganddependent transcription regulatory activity of PPAR-γ.
While our reporter gene assays indicated the highest levels of PPAR-γ-dependent transcription activity in JNK1-deficient cells (Fig. 6) , several PPAR-γ target genes, Abhd5 (e), Cebpa (f), Dgat1 (g) and Pparg (h) were examined using Taqman chemistry-based real-time qRT-PCR. All primers and probes were purchased from Applied Biosystems (Foster City, CA, USA). Eukaryotic 18S rRNA was used to normalise RNA sample loading. JNKI, JNK-intact; J1D, JNK1-deficient; J2D, JNK2-deficient; J12D, JNK1/JNK2-deficient adipocytes including Pepck, Cebpa, Slc2a4, and Gk, showed doseresponses to the reduction of JNK subtype protein, with the highest expression seen in JNK1/JNK2-deficient adipocytes (Table 1) . This difference is consistent with the hypothesis that JNK-regulated factors specifically present in adipocytes might act in concert with PPAR-γ-dependent and PPAR-γ-independent factors downstream of JNK to enhance transcription of these genes.
Discussion
Our data establish distinct and shared contributions of JNK1 and JNK2 to the regulation of adipocyte lipolysis and NEFA release, and can be summarised in four major findings. First, JNK1 and JNK2 are dispensable for adipocyte differentiation and cellular lipid accumulation. Second, combined JNK1/JNK2-deficiency accelerates basal lipolysis, whereas the alternate JNK subtype compensates for a single subtype deficiency in the regulation of basal lipolysis. Third, JNK1-deficiency is both necessary and sufficient to enhance NEFA re-esterification in adipocytes. Fourth, JNK1 and JNK2 have opposing roles in PPAR-γ-dependent reporter gene transcription in a pre-adipocyte cell background.
The amount of NEFA released from adipocytes, determined mainly by the balance between lipolysis and NEFA re-esterification, is regulated by energy demand and modulated by physiological and pathophysiological factors. Here, JNK1/JNK2-deficiency drastically enhanced basal lipolysis, whereas silencing Jnk1 or Jnk2 had no effect, suggesting a compensatory interplay between the two kinases in the regulation of basal lipolysis. Notably, insulin did not affect the kinetics of glycerol release in JNK-intact cells over a 120 min period, but increased glycerol release in JNK1-and JNK2-deficient cells at 120 min. Although both the acute and chronic stimulatory effects of insulin on adipocyte glycerol release have been demonstrated [39, 40] , this is the first report that JNK1-or JNK2-deficiency increases the stimulatory effect of insulin on glycerol release and that JNK1/JNK2-deficiency is more important in the regulation of lipolysis than insulin.
Intriguingly, the dramatically increased glycerol release associated with JNK1/JNK2-deficiency was not accompanied by a simultaneous increase in NEFA release over time. In addition, JNK1-deficiency, but not JNK2-deficiency, greatly decreased NEFA release without affecting glycerol release. We surmised that the observed discrepancy between lipolysis and NEFA release could be at least partially due to increased NEFA re-esterification. Measurements of NEFA release in the presence of triacsin C, which blocks NEFA re-esterification by inhibiting acyl-CoA synthetase, confirmed our prediction. Another interesting result is that insulin repressed net NEFA release in JNK-intact cells only during prolonged incubations of at least 120 min. Together with glycerol data, these indicate that during short-term incubation, insulin represses NEFA release through stimulation of NEFA re-esterification and not through inhibition of lipolysis. Insulin did not acutely alter NEFA release in JNK1-, JNK2-and JNK1/JNK2-deficient cells; however, the question of whether various types of JNK-deficiency will affect insulin response after a longer term exposure cannot be answered by our current study. Collectively, our data establish shared and distinct roles of JNK1 and JNK2 in the regulation of baseline lipolysis and NEFA release, and provide evidence linking the JNK pathway to the control of energy metabolism in adipocytes.
Both ligand-dependent and ligand-independent transactivation activities of PPAR-γ are inhibited by JNKmediated phosphorylation on its serine residue [38] ; therefore inactivation of JNK1 and/or JNK2 is expected to enhance PPAR-γ activity. Indeed, our genome-wide expression profiling showed that JNK1-, JNK2-and JNK1/ JNK2-deficiencies are associated with the upregulation of a subset of genes for triacylglycerol synthesis, NEFA reesterification and lipolysis, suggesting that both JNK1 and JNK2 are involved in the repression of a selective set of adipocyte-abundant genes. Interestingly, several PPAR-γ Results shown are luciferase (Luc) activity (mean±SEM) for three independent experiments relative to the basal value from control cells.
Comparisons were performed using ANOVA as described in the Methods. *p<0.05, ***p<0.0001
target genes including Pepck, Cebpa, Slc2a4 and Gk showed dose-responses to the reduction of JNK subtype protein, with the highest expression seen in JNK1/JNK2-deficient adipocytes (Table 1) . By contrast, some genes responded specifically to either JNK1-or JNK2-deficiencies (Fig. 3) , whereas a number of immune and inflammatory genes require both JNK1 and JNK2 for expression at levels similar to JNK-intact cells (Table 1) . It would be intriguing to identify the mechanism(s) by which various JNKdeficiencies differentially regulate adipocyte gene expression. However, such an undertaking would go beyond the scope of this report to the extent that a separate paper of interest would ensue. In a pre-adipocyte background, JNK1-deficiency enhanced both ligand-independent and ligand-dependent transactivation functions of PPAR-γ. Interestingly, a simultaneous loss of JNK2 attenuated the enhancement of liganded-PPAR-γ activity associated with JNK1-deficiency. This indicates that endogenous JNK1 represses and JNK2 promotes ligand-dependent PPAR-γ activity. The inhibitory activity of JNK1 is dominant, whereas the stimulatory action of JNK2 is revealed only when JNK1 is absent. In contrast to these reporter gene analyses, our microarray data demonstrated that JNK2-deficiency upregulated many PPAR-γ target genes in adipocytes, in many cases, to a similar extent to that seen in JNK1-deficiency (Table 1) , suggesting possible involvement of JNK-regulated factors specifically expressed in adipocytes. Taken together, our results suggest the likelihood of PPAR-γ being a critical target of both JNK1 and JNK2 in adipocytes, possibly through the phosphorylation of PPAR-γ and cofactors essential for PPAR-γ function.
Our data also demonstrate that both JNK1 and JNK2 are specifically required for the expression of the Jun family (Jun, Jund, Junb and Jundm2), but not the other adaptor protein-1 family members including Fosb, Atf2 and Elk1 (Table 1 ). The reductions in JUN production could contribute to the decreased expression of genes for immune and inflammatory responses. In addition, since JUN has been implicated in the repression of a number of genes [41] [42] [43] , the reduction in JUN protein can potentially activate transcription of a subset of genes normally repressed by JUN in adipocytes. Alternatively, the altered adipocyte gene expression could result from the interplay of a network of signalling proteins, whose expression and/or activities are affected by the various types JNK-deficiencies. Supporting this notion, our microarray data indicate that the mRNA levels of key proteins downstream of the insulin receptor such as phosphoinositide-3-kinase, thymoma viral protooncogene (AKT) 1, AKT2, ribosomal protein S6 kinase (p90) and extracellular regulated kinase-1 were all altered by JNK1-and/or JNK2-deficiencies ( Table 1 ). The exact mechanisms underlying the upregulation of adipocyteabundant genes associated with various JNK-deficiencies remain to be determined.
The drastic upregulation of PEPCK levels in JNK1/ JNK2-deficient adipocytes (Fig. 5) probably contributes to the enhanced rate of NEFA re-esterification by providing glycerol-3-phosphate. In parallel, the enhanced rate of NEFA re-esterification could reduce intracellular concentrations of long-chain fatty acyl-CoA (LC-CoA). As inferred from perfused rat adipocytes, intracellular LCCoA suppresses lipolysis by inhibiting triacylglycerol lipase activities [39, 44] ; therefore the induction of PEPCK protein by JNK1/JNK2-deficiency could also lead to increased lipolysis. On the other hand, JNK1-deficiency drastically decreased PEPCK protein levels while simultaneously increasing NEFA re-esterification. This indicates that PEPCK is not the only factor governing NEFA release; rather, multiple factors including the expression and activities of proteins involved in triacylglycerol turnover and insulin signalling are likely to be involved in the coordinate regulation of adipocyte NEFA release. Further studies are needed to identify the mechanisms underlying the distinct roles of JNK1 and JNK2 in the control of NEFA release.
Our data provide compelling evidence to define the shared and distinct roles of JNK1 and JNK2 in the regulation of adipocyte function in the context of gene expression, lipolysis and NEFA release. Studies of genetically altered mice suggest a possible differential function of each JNK subtype in different cell types [24] [25] [26] [27] . Thus, systemic inhibition of JNK would have limited translational value. Our studies showing that JNK1-deficiency inhibits baseline NEFA release suggest that inhibition of JNK1 activity could be a potential therapeutic approach for management of elevated NEFA levels at the onset of insulin resistance.
